Revisiting the Clinical Importance of DPYD*9A (c.85T>C) Variant of Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients Treated with Fluoropyrimidine-Based Chemotherapy.
作者信息
Patel Girijesh Kumar, Taylor William, Singh Seema, Khushman Moh'd, Singh Ajay P
机构信息
Department of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama, USA.
Medical Oncology, Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama, USA.
出版信息
J Mol Biomark Diagn. 2018;9(3). doi: 10.4172/2155-9929.1000e129. Epub 2018 Jun 18.
Abstract
摘要
相似文献
1
Revisiting the Clinical Importance of DPYD*9A (c.85T>C) Variant of Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients Treated with Fluoropyrimidine-Based Chemotherapy.
J Mol Biomark Diagn. 2018;9(3). doi: 10.4172/2155-9929.1000e129. Epub 2018 Jun 18.
2
The Prevalence of DPYD*9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis.
Clin Colorectal Cancer. 2019 Sep;18(3):e280-e286. doi: 10.1016/j.clcc.2019.04.005. Epub 2019 May 3.
3
Germline pharmacogenomics of DPYD*9A (c.85T>C) variant in patients with gastrointestinal malignancies treated with fluoropyrimidines.
J Gastrointest Oncol. 2018 Jun;9(3):416-424. doi: 10.21037/jgo.2018.02.03.
4
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Lancet Oncol. 2018 Nov;19(11):1459-1467. doi: 10.1016/S1470-2045(18)30686-7. Epub 2018 Oct 19.
5
Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.
Int J Cancer. 2019 May 1;144(9):2347-2354. doi: 10.1002/ijc.32022. Epub 2019 Jan 4.
6
DPYD gene polymorphisms are associated with risk and chemotherapy prognosis in pediatric patients with acute lymphoblastic leukemia.
Tumour Biol. 2016 Aug;37(8):10393-402. doi: 10.1007/s13277-016-4908-2. Epub 2016 Feb 4.
7
DPYD, TYMS and MTHFR Genes Polymorphism Frequencies in a Series of Turkish Colorectal Cancer Patients.
J Pers Med. 2018 Dec 13;8(4):45. doi: 10.3390/jpm8040045.
8
Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population.
Cancer Chemother Pharmacol. 2004 May;53(5):445-51. doi: 10.1007/s00280-003-0749-y.
9
Rare Dihydropyrimidine Dehydrogenase Variants and Toxicity by Floropyrimidines: A Case Report.
Front Oncol. 2019 Mar 11;9:139. doi: 10.3389/fonc.2019.00139. eCollection 2019.
10
Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity.
Int J Cancer. 2015 Feb 1;136(3):730-9. doi: 10.1002/ijc.29025. Epub 2014 Jun 27.
引用本文的文献
1
Purine Metabolism Dysfunctions: Experimental Methods of Detection and Diagnostic Potential.
Int J Mol Sci. 2023 Apr 10;24(8):7027. doi: 10.3390/ijms24087027.
本文引用的文献
1
Germline pharmacogenomics of DPYD*9A (c.85T>C) variant in patients with gastrointestinal malignancies treated with fluoropyrimidines.
J Gastrointest Oncol. 2018 Jun;9(3):416-424. doi: 10.21037/jgo.2018.02.03.
2
DPYD*2A/*5A/*9A and UGT1A1*6/*28 polymorphisms in Chinese colorectal cancer patients.
J Cancer Res Ther. 2016 Apr-Jun;12(2):782-6. doi: 10.4103/0973-1482.148685.
3
Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
Cancer Chemother Pharmacol. 2015 Apr;75(4):763-72. doi: 10.1007/s00280-015-2698-7. Epub 2015 Feb 13.
4
Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity.
Cancer Res. 2014 May 1;74(9):2545-54. doi: 10.1158/0008-5472.CAN-13-2482. Epub 2014 Mar 19.
5
Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.
Pharmacogenomics. 2009 Jun;10(6):931-44. doi: 10.2217/pgs.09.28.
6
Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy.
Neoplasma. 2009;56(4):303-16. doi: 10.4149/neo_2009_04_303.
7
Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients.
PLoS One. 2008;3(12):e4003. doi: 10.1371/journal.pone.0004003. Epub 2008 Dec 23.
8
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
N Engl J Med. 2007 Oct 25;357(17):1695-704. doi: 10.1056/NEJMoa071028.
9
Suppression of DPYD expression in RKO cells via DNA methylation in the regulatory region of the DPYD promoter: a potentially important epigenetic mechanism regulating DPYD expression.
Biochem Cell Biol. 2007 Jun;85(3):337-46. doi: 10.1139/o07-009.
10
Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer.
Oncologist. 2006 Apr;11(4):325-35. doi: 10.1634/theoncologist.11-4-325.
Zotero 插件